Damon R Reed MD
Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology
Member, Memorial Hospital Memorial Sloan Kettering Cancer Center Solid Tumor Division Director, MSK Kids President, Connective Tissue Oncology Society Vice Chair, Bone Tumor Committee, COG
Request appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Reed
Damon Reed currently serves as the Solid Tumor Division Director at MSK Kids, Memorial Solid Tumor Group.
Dr. Reed is experienced in treating young adult and pediatric patients with conditions such as osteosarcoma, Ewing sarcoma, soft tissue sarcomas, including rhabdomyosarcoma.
He develops clinical trials and is a team scientist with numerous publications and leadership roles.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 2005 - 2008
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2002 - 2005
Case Western Reserve University School of MedicineClass of 2002
Certifications & Licensure
NJ State Medical License 2025 - 2027
NY State Medical License 2023 - 2027
FL State Medical License 2008 - 2026
TN State Medical License 2005 - 2010
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- President, Connective Tissue Oncology Society CTOS, 2024
- Mentor of the Year Children’s Oncology Group, 2023
- Leader, Sunshine Project National Pediatric Cancer Foundation (NPCF) 2011-2023, 2022
Clinical Trials
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
- SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
- Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Start of enrollment: 2016 Oct 25
Publications & Presentations
PubMed
- Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Childr...Safia K Ahmed, Odion Binitie, Mark Krailo, Daniel J Indelicato, Alexandra K Callan
International Journal of Radiation Oncology, Biology, Physics. 2026-06-01 - Adaptive and sequential cancer therapies emerge from treatment schedule optimization.Charles D Kocher, Joseph O Deasy, Damon R Reed, Larry Norton, Corey Weistuch
Research Square. 2026-05-29 - An international framework for clinical translation of molecular classifiers in osteosarcoma.Amanda E Marinoff, Michaela Nathrath, David S Shulman, Sarah B Whittle, Jovana Pavisic
NPJ Precision Oncology. 2026-05-05
Press Mentions
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma ConferenceJune 30th, 2025
Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1/2 Clinical TrialJuly 29th, 2020
SP-2577 Granted Fast Track Designation by the FDA for Patients with Ewing SarcomaDecember 16th, 2019
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
Blue Shield California HMO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOCoventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Health Net California Large Group PPO
Health Net HMO - Employer Group
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
Pacificare HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Wellmark Alliance Select - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
